Deltex Medical Regulatory News (DEMG)

18 November 2015

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Open access e-learning courses launched

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), is pleased to announce that it has launched its first open access ODM online e-learning courses.

The UK version is at http://deltexmedical.education/en/ and the US version at http://deltexmedical.education/us/. The Company plans to make the first Spanish modules available shortly and is working towards versions in other languages with local distribution and academic partners.

E-learning allows customers to learn the fundamentals of ODM in private and at their own pace. Earlier iterations launched over the last half year were only accessible through licences purchased from the platform provider and sponsored by the Company.

Where the Company has deployed its e-learning to date, it has been able to train more staff, at a faster rate to become independent users of ODM. The Company is planning to add additional modules covering more advanced uses of ODM in due course.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We have been very pleased with the response to our e-learning packages, particularly in the USA, where we are focused on converting significant numbers of staff to ODM users in platform accounts. Our new online platform is more flexible, requires lower grade broadband access and avoids the cost and administrative burden of individual user licences."

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.